USFDA classifies Cipla’s Patalganga manufacturing facility as Voluntary Action Indicated

25 Jun 2024 Evaluate

United States Food and Drug Administration (USFDA) has classified Cipla’s Patalganga manufacturing facility as Voluntary Action Indicated (VAI). USFDA had concluded routine current Good Manufacturing Practices (cGMP) inspection at Cipla’s said facility from March 28, 2024 to April 4, 2024. On conclusion of the inspection, the company had received 6 inspectional observations in Form 483.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1369.55 -8.30 (-0.60%)
21-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.55
Dr. Reddys Lab 1155.50
Cipla 1369.55
Zydus Lifesciences 876.10
Lupin 2139.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×